FMP

FMP

Enter

PTCT - PTC Therapeutics, In...

photo-url-https://images.financialmodelingprep.com/symbol/PTCT.png

PTC Therapeutics, Inc.

PTCT

NASDAQ

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

57.17 USD

2.67 (4.67%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Revenue %

-

114

-35.71

67.84

-40.11

23.01

23.01

23.01

23.01

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Operating Cash Flow %

258.95

-177.05

-326.92

-130.84

-413.2

-60

-60

-60

-60

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Cap Ex %

-26.73

-2.19

-6.06

-43.87

-27.27

-21.22

-21.22

-21.22

-21.22

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Weighted Average Cost Of Capital

Price

34.49

Beta

Diluted Shares Outstanding

75.04M

Costof Debt

4.11

Tax Rate

After Tax Cost Of Debt

4.11

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

87.76M

Total Equity

2.59B

Total Capital

2.68B

Debt Weighting

3.28

Equity Weighting

96.72

Wacc

14.27

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Wacc

14.27

14.27

14.27

14.27

14.27

Pv Lfcf

-41.16M

-44.3M

-47.68M

-51.33M

-55.25M

Sum Pv Lfcf

-239.72M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

14.27

Free Cash Flow T1

-109.82M

Terminal Value

-894.7M

Present Terminal Value

-459.12M

Intrinsic Value

Enterprise Value

-698.84M

Net Debt

-32.49M

Equity Value

-666.35M

Diluted Shares Outstanding

75.04M

Equity Value Per Share

-8.88

Projected DCF

-8.88 4.884%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep